Eli Lilly 2013 Annual Report Download - page 136

38
Executive Compensation
Summary Compensation Table
Name and
Principal Position Year
Salary
($)
Bonus
($)
Stock
Awards
($) 1
Option
Awards
($)
Non-Equity
Incentive Plan
Compensation
($) 2
Change
in Pension
Value
($) 3
All
Other
Compensation
($) 4
Total
Compensation
($)
John C. Lechleiter, Ph.D. 2013 $1,500,000 $0 $6,750,000 $0 $2,877,000 $0 5$90,000 $11,217,000
Chairman, President, and
Chief Executive Officer 2012 $1,500,000 $0 $5,625,000 $0 $2,982,000 $4,423,633 $90,000 $14,620,633
2011 $1,500,000 $0 $5,625,000 $0 $2,625,000 $6,530,094 $90,000 $16,370,094
Derica W. Rice 2013 $1,014,750 $0 $2,850,000 $0 $1,251,187 $0 5$60,885 $5,176,822
Executive Vice President,
Global Services and
Chief Financial Officer
2012 $990,000 $0 $2,850,000 $0 $1,265,220 $1,770,767 $59,400 $6,935,387
2011 $984,167 $0 $2,850,000 $0 $1,107,188 $940,589 $59,050 $5,940,993
Jan M. Lundberg, Ph.D. 2013 $1,002,963 $0 $2,250,000 $0 $1,236,653 $224,741 $60,178 $4,774,535
Executive Vice President,
Science and Technology
and President, Lilly
Research Laboratories
2012 $978,500 $0 $2,250,000 $0 $1,250,523 $307,275 $58,710 $4,845,008
2011 $973,750 $0 $2,062,500 $0 $1,095,469 $232,128 $58,425 $4,422,272
Michael J. Harrington 2013 $765,000 $0 $1,312,500 $0 $786,038 $264,784 $45,900 $3,174,222
Senior Vice President and
General Counsel 2012 N/A N/A N/A N/A N/A N/A N/A N/A
2011 N/A N/A N/A N/A N/A N/A N/A N/A
Enrique A. Conterno 2013 $680,658 $0 $1,500,000 $0 $699,376 $88,167 $40,840 $3,009,041
Senior Vice President and
President, Lilly Diabetes 2012 $669,500 $0 $1,500,000 $0 $713,018 $992,187 $40,170 $3,914,875
2011 $666,250 $0 $1,500,000 $0 $624,609 $887,380 $39,975 $3,718,214
1 This column shows the grant date fair value of PAs and SVAs computed in accordance with FASB ASC
Topic 718. Values for awards subject to performance conditions (PAs) are computed based upon the probable
outcome of the performance condition as of the grant date. A discussion of assumptions used in calculating
award values may be found in Note 11 to our 2013 audited financial statements in our Form 10-K.
The table below shows the minimum, target, and maximum payouts (using the grant date fair value) for the
2013-2014 PA grant included in this column of the Summary Compensation Table.
Name Payout Date Minimum Payout Target Payout Maximum Payout
Dr. Lechleiter January 2015 $0 $4,500,000 $6,750,000
Mr. Rice January 2015 $0 $1,900,000 $2,850,000
Dr. Lundberg January 2015 $0 $1,500,000 $2,250,000
Mr. Harrington January 2015 $0 $875,000 $1,312,500
Mr. Conterno January 2015 $0 $1,000,000 $1,500,000
2
Payments for 2013 performance were made in March 2014 under the bonus plan. All bonuses paid to named
executive officers were part of a non-equity incentive plan.
3
The amounts in this column reflect the change in pension value for each individual, calculated by our actuary,
and are impacted by the discount rate, pay earned in the last ten years, age, and years of service. No named
executive officer received preferential or above-market earnings on deferred compensation.
4
The amounts in this column are solely company matching contributions for each individual's 401(k) plan
contributions. The company does not reimburse executives for taxes outside of the limited circumstance of taxes
related to employee relocation or a prior international assignment. There were no perquisites or payments to
report in the proxy statement.
5
The net present value of the pension benefits for Dr. Lechleiter and Mr. Rice reflect no change from 2012 due to
an increase in the discount rate as reflected in footnote 1 to the pension benefits table below. For the other
named executive officers, increases in pensionable earnings offset the impact of the increased discount rate.